Alzheimer's disease: Psychopathology, medical management and dental implications

Journal of the American Dental Association

Volumn 137, Issue 9, 2006, Pages 1240-1251

  Friedlander, Arthur H ^a,b,c   Norman, Dean C ^a,d   Mahler, Michael E ^a,d   Norman, Keith M ^a   Yagiela, John A ^c,d  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UCLA SCHOOL OF DENTISTRY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Dental treatment

Indexed keywords

EID: 33749327547     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2006.0381     Document Type: Article

References (108)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington: American Psychiatric Association; 2000:147-58.
2. Cummings JL. Alzheimer's disease. N Engl J Med 2004;35(1):56-67.
3. Reisberg B, Ferris SH, De Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139(9):1136-9.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44.
5. Reisberg B, Ferris SH, de Leon MJ, et al. The stage specific temporal course of Alzheimer's disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation. Prog Clin Biol Res 1989;317:23-41.
6. Capitani E, Cazzaniga R, Francescani A, Spinnler H. Cognitive deterioration in Alzheimer's disease: is the early course predictive of the later stages? Neural Sci 2004;25(4):198-204.
7. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996;8(supplement 3):497-500.
8. Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75(9):1327-30.
9. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26(4):494-504.
10. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46(1):130-5.
11. Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 1993;33(6):714-20.
12. Frenkel H. Alzheimer's disease and oral care. Dent Update 2004;31(5):273-4, 276-8.
13. Kalia M. Dysphagia and aspiration pneumonia in patients with Alzheimer's disease. Metabolism 2003;52(10 supplement 2):36-8.
14. Horner J, Alberts MJ, Dawson DV, Cook GM. Swallowing in Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8(3):177-89.
15. Chouinard J. Dysphagia in Alzheimer's disease: a review. J Nutr Health Aging 2000;4(4):214-7.
16. Wada H, Nakajoh K, Satoh-Nakagawa T, et al. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology 2001;47(5):271-6.
17. Gillick MR. Rethinking the role of tube feeding in patients with advanced dementia. N Engl J Med 2000;342(3):206-10.
18. Gitto CA, Moroni MJ, Terezhalmy GT, Sandu S. The patient with Alzheimer's disease. Quintessence Int 2001;32(3):221-31.
19. Navazesh M, Mulligan R. Systemic dissemination as a result of oral infection in individuals 50 years of age and older. Spec Care Dentist 1995;15(1):11-9.
20. Chouinard J, Lavigne E, Villeneuve C. Weight loss, dysphagia, and outcome in advance dementia. Dysphagia 1998;13(3):151-5.
21. Priefer BA, Robbins J. Eating changes in mild-stage Alzheimer's disease: a pilot study. Dysphagia 1997;12(4):212-21.
22. Limeback H. Implications of oral infections on systemic diseases in the institutionalized elderly with a special focus on pneumonia. Ann Periodontol 1998;3(1):262-75.
23. Scannapieco FA, Papandonatos GD, Dunford RG. Associations between oral conditions and respiratory disease in a natural sample survey population. Ann Periodontol 1998;3(1):251-6.
24. Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56(1):49-56.
25. Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 2004;52(2):195-204.
26. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60(8):1119-22.
27. Karp A, Kareholt I, Qiu C, Bellander T, Winblad B, Fratiglioni L. Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. Am J Epidemiol 2004;159(2):175-83.
28. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81-104.
29. Mattson MP. Gene-diet interactions in brain aging and neurodegenerative disorders. Ann Intern Med 2003;139(5 part 2):441-4.
30. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003;6(4):345-51.
31. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64(2):277-81.
32. Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry 2005;62(5):565-73.
33. Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, Martins RN. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 2004;50(4):397-409.
34. Bertram L, Tanzi RE. The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res 2004;50(4):385-96.
35. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44(1):181-93.
36. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430(7000):631-9.
37. Tanaka Y, Meguro K, Yamaguchi S, et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann Nucl Med 2003;17(7):567-73.
38. Wang H, Shu L, Xie J, Zhang H, Zhang D. Diagnostic utility of neuropsychological performance and quantitative MRI-based measurement in Alzheimer disease. Alzheimer Dis Assoc Disord 2004;18(3):163-70.
39. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143-53.
40. Scarmeas N, Habeck CG, Zarahn E, et al. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage 2004;23(1):35-45.
41. Hirono N, Hashimoto M, Ishii K, Kazui H, Mori E. One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2004;16(4):488-92.
42. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98.
43. Wang H, Shu L, Xie J, Zhang H, Zhang D. Diagnostic utility of neuropsychological performance and quantitative MRI-based measurement in Alzheimer disease. Alzheimer Dis Assoc Disord 2004;18(3):163-70.
44. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998;53:127-40.
45. Courtney C, Farrell D, Gray R, et al.; AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 2004;363(9427):2105-15.
46. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004;11(11):734-41.
47. Johannsen P. Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs 2004;18(12):757-68.
48. Colombres M, Sagal JP, Inestrosa NC. An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. Curr Pharm Des 2004;10(25):3121-30.
49. Zhang L, Zhou FM, Dani JA. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 2004;66(3):538-44.
50. Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 2004;3(5):425-40.
51. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by β-amyloid (1-40). Brain Res 2002;958(1):210-21.
52. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004;19(10):919-25.
53. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45(5):583-95.
54. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Mobius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41.
55. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336(17):1216-22.
56. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's Disease, part II: treatment. Am Fam Physician 2002;65(12):2525-34.
57. Sultzer D, Cummings JL. Alzheimer's disease. In: Rakel RE, Conn HF, eds. Current therapy, 1993: Latest approved methods of treatment for the practicing physician. Philadelphia: Saunders; 1993:838-40.
58. Finkel SI. Managing the behavioral and psychological signs and symptoms of dementia. Int Clin Psychopharmacol 1997;12(supplement 4):S25-S28.
59. Mintzer JE. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. J Clin Psychiatry 2001;62(supplement 21):23-5.
60. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44(8):778-83.
61. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001;62(supplement 21):15-8.
62. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomized comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16(12):1156-62.
63. Johannessen CU. Mechanisms of action of valproate: a commentary. Neurochem Int 2000;37(2-3):103-10.
64. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind placebo-controlled, multicenter study. European Valproate Mania Study. J Clin Psychopharmacol 2000;20(2):195-203.
65. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57(5):481-9.
66. Post RM, Weiss SRB, Chuang DM, Ketter TA. Mechanisms of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in mood disorders. New York: M. Dekker; 1994:43-92.
67. Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001;9(4):346-60.
68. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA 1997;278(14):1186-90.
69. Physicians' desk reference. 59th ed. Oradell, N.J.: Medical Economics; 2005.
70. McEvoy GK. AHFS drug information 2005. Bethesda, Md.: American Society of Health-System Pharmacists; 2005.
71. Friedlander AH, Marder SR. The psychopathology, medical management and dental implications of schizophrenia. JADA 2002;133(5):603-10.
72. Arai K, Sumi Y, Uematsu H, Miura H. Association between dental health behaviors, mental/physical function and self-feeding ability among the elderly: a cross-sectional survey. Gerodontology 2003;20(2):78-83.
73. Ship JA, DeCarli C, Friedland RP, Baum BJ. Diminished submandibular salivary flow in dementia of the Alzheimer type. J Gerontol 1990;45(2):M61-6.
74. Ship JA, Puckett SA. Longitudinal study on oral health in subjects with Alzheimer's disease. J Am Geriatr Soc 1994;42(1):57-63.
75. Chiappelli F, Bauer J, Spackman S, et al. Dental needs of the elderly in the 21st century. Gen Dent 2002;50(4):358-63.
76. Ship JA. Oral health of patients with Alzheimer's disease. JADA 1992;123(1):53-8.
77. Jones JA, Lavallee N, Alman J, Sinclair C, Garcia RI. Caries incidence in patients with dementia. Gerodontology 1993;10(2):76-82.
78. Henry RG. Alzheimer's disease and cognitively impaired elderly: providing dental care. J Calif Dent Assoc 1999;27(9):709-17.
79. Friedlander AH, Jarvik LF. The dental management of the patient with dementia. Oral Surg Oral Med Oral Pathol 1987;64(5):549-53.
80. Kocaelli H, Yaltirik M, Yargic LI, Ozbas H. Alzheimer's disease and dental management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93(5):521-4.
81. Henry RG, Wekstein DR. Providing dental care for patients diagnosed with Alzheimer's disease. Dent Clin North Am 1997;41(4):915-43.
82. Nordenram G, Ryd-Kjellén E, Ericsson K, Winblad B. Dental management of Alzheimer patients: a predictive test of dental cooperation in individualized treatment planning. Acta Odontol Scand 1997;55(3):148-54.
83. Niessen LC, Jones JA. Professional dental care for patients with dementia. Gerodontology 1987;6(2):67-71.
84. Henry R, Smith B. Treating the Alzheimer's patient: a guide for dental professionals. J Mich Dent Assoc 2004;86(10):32-6, 38-40, 42 passim.
85. Ostuni E, Mohl G. Communicating more effectively with the confused or demented patient. Gen Dent 1995;43(3):264-6.
86. Henry RG. Neurologic disorders in dentistry: managing patients with Alzheimer's disease. J Indiana Dent Assoc 1997-1998;76(4):51-7.
87. McCann D. Treating patients with Alzheimer's disease: the challenges and rewards. CDS Rev 2000;93(4):10-3.
88. Ocasio NA, Solomowitz BH, Sher MR. Dental management of the patient with Alzheimer's disease. N Y State Dent J 2000;66(3):32-5.
89. Tips for managing patients with Alzheimer's disease. Dent Assist 2003;72(4):14, 31.
90. Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging 2003;20(6):437-44.
91. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003;17(13):947-63.
92. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993;13(1):57-67.
93. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15(6):387-98.
94. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series. JADA 1999;130(3):397-407.
95. Callahan AM, Marangell LB, Ketter TA. Evaluating the clinical significance of drug interactions: a systematic approach. Harv Rev Psychiatry 1996;4(3):153-8.
96. Hersh EV, Moore PA. Drug interactions in dentistry: the importance of knowing your CYPs. JADA 2004;135(3):298-311.
97. Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors, part V of a series. JADA 1999;130(5):701-9.
98. Ettinger RL. Dental management of patients with Alzheimer's disease and other dementias. Gerodontology 2000;17(1):8-16.
99. Blanco VL, Levy SM, Ettinger RL, Logan H, Buckwalter KC. Challenges in geriatric oral health research methodology concerning caregivers of cognitively impaired elderly adults. Spec Care Dentist 1997;17(4):129-32.
100. Moody GH, Drummond JR, Newton JP. Alzheimer's disease. Br Dent J 1990;169(2):45-7.
101. Lapeer GL. Dementia's impact on pain sensation: a serious clinical dilemma for dental geriatric care givers. J Can Dent Assoc 1998;64(3):182-4, 187-92.
102. Carr-Hosie MA. Treatment considerations for the dental professional for patients with Alzheimer's disease. J Okla Dent Assoc 1993;83(3):36-42.
103. Naftalin LW, Yagiela JA. Vasoconstrictors: indications and precautions. Dent Clin North Am 2002;46(4):733-46.
104. Ganzberg S. Psychoactive drugs. In: Ciancio SG, ed. ADA guide to dental therapeutics. 3rd ed. Chicago: American Dental Association; 2003:383-411.
105. Galli MT, Henry RG. Using intravenous sedation to manage adults with neurological impairment. Spec Care Dentist 1999;19(6):275-80.
106. Ferrell BA. Pain management. Clin Geriatr Med 2000;16(4):853-74.
107. Heath ML. Donepezil and succinylcholine. Anaesthesia 2003;58(2):202.
108. Crowe S, Collins L. Suxamethonium and donepezil: a cause of prolonged paralysis. Anesthesiology 2003;98(2):574-5.